Medical/Pharmaceuticals
Telix Announces Executive Leadership Appointments
MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. Richard Valei...
2022-12-05 06:39
3073
Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022
JINAN, China, Dec. 4, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies inChina that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study...
2022-12-04 17:00
2187
JelloX Biotech Leads Research in 3D Cancer Pathology as NCI Explores Potential
SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- JelloX Biotech is celebrating a robust year of research and product development milestones while showcasing the potential for 3D imaging and AI to be the future of cancer pathology. Presently, most cancer diagnosis is done through thinly sliced physic...
2022-12-03 09:58
3317
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
HAIKOU, China, Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onDecember 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NY...
2022-12-03 05:10
4622
Lakeshore Acquisition Corp I Shareholders Approve Business Combination with ProSomnus
SAN FRANCISCO, Dec. 2, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (Nasdaq: LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus"...
2022-12-03 05:05
4849
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS
The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis MIAMI, Dec. 3, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a$5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmen...
2022-12-03 01:07
5071
Epiprotect reduces the cost for treatment of hard to heal leg ulcers with 83%
LINKÖPING, Sweden, Dec. 3, 2022 /PRNewswire/ -- A compilation of data from patients treated at S2Clinic during the period 2019-2022 showed that the cost of treatment of these patients was reduced by approximately 83% compared to conventional treatment. The treatment with Epiprotect also resulted ...
2022-12-03 00:41
3642
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
CEO Lance Kawaguchi Drives Effort & Brings Compelling Personal Story to Global Battle Against Cancer NEW YORK, Dec. 3, 2022 /PRNewswire/ -- Cure Brain Cancer Foundation CEO Lance Kawaguchi rang the bell to open trading on the Nasdaq stock exchange on Friday morning,December 2. The Foundation ann...
2022-12-02 23:00
3747
Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 - Lights up NY Times Square, NASDAQ
TAMPA, Fla., Dec. 2, 2022 /PRNewswire/ -- VEITH 2022 witnessed a surge of
supporting clinical data for Sirolimus Coated Balloon in the treatment of
Below-the-Knee (BTK) disease.Concept Medical Inc
2022-12-02 21:10
5410
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "...
2022-12-02 18:23
4903
Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022
JINAN, China, Dec. 2, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies inChina that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study...
2022-12-02 16:20
2067
Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering
SYDNEY, Dec. 2, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the "Rights Offering") for qualifying shareholders of record as ofDecember 6, 20...
2022-12-02 10:05
5363
Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
BEIJING, SHANGHAI and BOSTON, Dec. 1, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination withSHP2 inhibitor JAB-3312 in preclinical cancer models in a poster session during the 2022 European Society of Medica...
2022-12-02 08:30
2496
Innoforce Opens GMP Manufacturing Facility & Corporate Headquarters in Hangzhou, China to Provide CDMO Services for Global Supply of RNA, Cell & Gene Therapies
The new site adds to its capacity in China & US to provide end-to-end process development and global manufacturing services for advanced therapies HANGZHOU, China, Dec. 2, 2022 /PRNewswire/ -- Innoforce, a global provider of end-to-end contract development and manufacturing services (CDMO), today...
2022-12-02 06:00
4292
Armis Named Clear Leader in SPARK Matrix for Connected Medical Device Security Solutions
Company recognized for comprehensive and robust asset intelligence platform; ranked highest among competitors for technology excellence and customer impact SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Armis, the leading asset visibility and security company, today announced that it has been named ...
2022-12-01 22:50
2942
HAVAS HEALTH & YOU EXPANDS CONTENT EXPERTISE THROUGH PARTNERSHIP WITH EVERMED
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COVID-19 dramatically changed the way doctors interact with the health industry – they're looking for more convenient and efficient ways to consume medical information than ever, leading to an uptick in demand for content. To help address the need for more c...
2022-12-01 22:15
3144
Creating the Leaders of Tomorrow: The Valuable 500 Reach Milestone for 'Generation Valuable' on International Day for Persons with Disabilities
* Powered by Verizon, the Valuable 500 has enlisted 75 Generation Valuable Mentees and Mentors * Launching in January 2023, the Generation Valuable participants will gain access to world-class creative leadership courses and collaborative opportunities with the other multinational corporation...
2022-12-01 21:27
2135
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine. ...
2022-12-01 21:00
5869
Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met
SUZHOU, China, Dec. 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced results of phase II clinical trial of pyrilutamide (KX-826), a poten...
2022-12-01 19:30
2869
111, Inc. Announces Third Quarter 2022 Unaudited Financial Results
SHANGHAI, Dec. 1, 2022 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the third quarter...
2022-12-01 15:33
3682
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
26162
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
15075
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
14557
OceanaGold Reports Third Quarter 2026 Results
2026-11-05 06:52
14412